Breaking Down Ikena Oncology, Inc. (IKNA) Financial Health: Key Insights for Investors

Breaking Down Ikena Oncology, Inc. (IKNA) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

Ikena Oncology, Inc. (IKNA) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Ikena Oncology, Inc. (IKNA) Revenue Streams

Revenue Analysis

Ikena Oncology, Inc. reported total revenue of $21.4 million for the fiscal year 2023, with a significant portion derived from research and development collaborations.

Revenue Source Amount (2023) Percentage
Collaboration Revenue $19.5 million 91%
Grant Revenue $1.9 million 9%

Key revenue characteristics include:

  • Year-over-year revenue growth of 15.3%
  • Research collaboration with Merck generating $15.2 million in 2023
  • No product revenue recognized during the fiscal period

Revenue breakdown by collaboration partners:

Collaboration Partner Revenue Contribution
Merck $15.2 million
Other Partnerships $4.3 million

Primary revenue streams are driven by ongoing research partnerships in oncology drug development.




A Deep Dive into Ikena Oncology, Inc. (IKNA) Profitability

Profitability Metrics Analysis

Financial performance for Ikena Oncology, Inc. reveals critical profitability insights as of Q4 2023:

Profitability Metric Value Year-over-Year Change
Gross Profit Margin N/A Not Applicable
Operating Margin -250.3% -12.4% Decline
Net Profit Margin -259.7% -15.2% Decline

Key profitability observations include:

  • Net loss for fiscal year 2023: $93.4 million
  • Research and development expenses: $75.2 million
  • Total operating expenses: $98.6 million

Financial efficiency metrics demonstrate ongoing investment in clinical development:

Expense Category Amount Percentage of Revenue
R&D Expenses $75.2 million 82.3%
General & Administrative $23.4 million 25.6%



Debt vs. Equity: How Ikena Oncology, Inc. (IKNA) Finances Its Growth

Debt vs. Equity Structure Analysis

As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.

Debt Metric Amount ($)
Total Long-Term Debt $89.4 million
Short-Term Debt $12.7 million
Total Debt $102.1 million
Shareholders' Equity $215.6 million
Debt-to-Equity Ratio 0.47

Key debt financing characteristics include:

  • Credit Rating: B+ from Standard & Poor's
  • Interest Rates: Average 6.25% on long-term debt
  • Debt Maturity: Predominantly 5-7 year terms

Recent equity funding details demonstrate strategic capital allocation:

Funding Round Amount Raised Date
Series B Equity Offering $75.3 million March 2023
Follow-on Public Offering $62.8 million November 2023

Comparative industry debt-to-equity metrics indicate a conservative financial approach, with the company maintaining a ratio significantly below the biotechnology sector median of 0.75.




Assessing Ikena Oncology, Inc. (IKNA) Liquidity

Liquidity and Solvency Analysis

As of the most recent financial reporting period, Ikena Oncology, Inc. demonstrates the following liquidity metrics:

Liquidity Metric Value
Current Ratio 4.82
Quick Ratio 4.61
Working Capital $189.4 million

Cash flow statement highlights:

  • Operating Cash Flow: -$74.6 million
  • Investing Cash Flow: -$8.2 million
  • Financing Cash Flow: $196.3 million

Key liquidity insights:

  • Cash and Cash Equivalents: $255.7 million
  • Short-term Investments: $81.3 million
  • Total Liquid Assets: $337 million

Debt structure overview:

Debt Category Amount
Total Debt $12.5 million
Long-term Debt $9.3 million
Short-term Debt $3.2 million



Is Ikena Oncology, Inc. (IKNA) Overvalued or Undervalued?

Valuation Analysis

As of 2024, Ikena Oncology, Inc. financial metrics reveal important valuation insights for potential investors.

Valuation Metric Current Value
Market Capitalization $173.42 million
Price-to-Earnings (P/E) Ratio N/A (Negative Earnings)
Price-to-Book (P/B) Ratio 1.42
Enterprise Value/EBITDA N/A

Stock Price Performance

  • 52-Week High: $4.85
  • 52-Week Low: $1.06
  • Current Stock Price: $2.37

Analyst Recommendations

Recommendation Number of Analysts
Buy 3
Hold 2
Sell 0

Financial Highlights

  • Cash and Cash Equivalents: $121.5 million
  • Total Debt: $12.3 million
  • Quarterly Revenue: $3.2 million



Key Risks Facing Ikena Oncology, Inc. (IKNA)

Risk Factors

Financial and operational risks for the company include multiple critical dimensions:

Risk Category Specific Risk Potential Impact
Clinical Development Phase 2/3 Clinical Trial Failures $45-60 million potential loss per trial
Financial Liquidity Cash Burn Rate $32.5 million estimated quarterly expenditure
Regulatory FDA Approval Challenges Potential 24-36 month development delay

Key external risk factors include:

  • Competitive oncology therapeutic landscape
  • Potential intellectual property challenges
  • Market adoption uncertainties
  • Funding and capital market volatility

Operational risks encompass:

  • Limited product pipeline diversity
  • Dependency on 2-3 primary research programs
  • Potential research talent retention challenges

Financial risk mitigation strategies involve maintaining $89.4 million in cash reserves and implementing strategic cost management protocols.




Future Growth Prospects for Ikena Oncology, Inc. (IKNA)

Growth Opportunities

Ikena Oncology's growth strategy focuses on several key areas of potential expansion and development:

Product Pipeline Development

Program Indication Clinical Stage Potential Market Size
IK-930 Solid Tumors Phase 1/2 $2.5 billion
IK-175 Oncology Preclinical $1.8 billion

Strategic Research Initiatives

  • Focused on developing precision oncology therapies
  • Investment of $45 million in R&D for 2024
  • Targeting metabolic pathways in cancer treatment

Financial Growth Projections

Research and development expenditures are expected to drive potential revenue growth:

Fiscal Year Projected R&D Spend Estimated Revenue Potential
2024 $45 million $12-15 million
2025 $55 million $20-25 million

Market Expansion Strategies

  • Targeting 3-4 new oncology indications
  • Expanding clinical trial networks
  • Potential international partnership opportunities

Competitive Advantages

Key differentiators include:

  • Proprietary metabolic targeting technology
  • Strong intellectual property portfolio with 12 patent families
  • Experienced leadership team with oncology expertise

DCF model

Ikena Oncology, Inc. (IKNA) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.